Hepatotoxicity associated with statins

Main Article Content

Bensu Karahalil Emine Hare Göksel Koç İrem Çelik Kerem Şentürk Yağmur Özkan


Treatment with statins is known all over the world. They are generally considered safe at therapeutic doses. Nevertheless, clinical trials are not enough to assess their scarce adverse effects such as idiosyncratic drug induced liver injury (DILI). Due to some conditions, such as concomitant usage (drug-drug interaction using an identical metabolising enzyme) and genetic polymorphisms, there is an increasing concern about their safety. Hepatotoxicity and rhabdomyolysis have begun to appear in published studies. Most of investigations have focused on both these adverse effects and mechanisms of drug induced toxicity. The present review has attempted to compile almost all of the existing studies on the hepatotoxicity of statins but not rhabdomyolysis. The aim of our study is to provide an overview of the studies on the statin-associated hepatotoxicity and to discuss the published studies. The researchers are of the opinion that the research on this topic is incomplete but extremely necessary.

Article Details

How to Cite
KARAHALIL, Bensu et al. Hepatotoxicity associated with statins. Archives of Industrial Hygiene and Toxicology, [S.l.], v. 68, n. 4, oct. 2017. ISSN 1848-6312. Available at: <https://arhiv.imi.hr/index.php/arhiv/article/view/790>. Date accessed: 25 may 2018. doi: https://doi.org/10.1515/aiht-2017-68-2994.